Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDE8B | O95263 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20139067 | 1.00 | PARP1 (0.49) | PARP1ALDH1A1HSD17B10ATMSMN1; SMN2 | |
| SCHEMBL20139068 | 1.00 | PARP1 (0.49) | PARP1ALDH1A1HSD17B10ATMSMN1; SMN2 | |
| SCHEMBL336577 | 0.91 | PARP1 (0.54) | PARP1ALDH1A1HSD17B10ATMSMN1; SMN2 | |
| SCHEMBL336578 | 0.91 | PARP1 (0.54) | PARP1ALDH1A1HSD17B10ATMSMN1; SMN2 | |
| SCHEMBL337351 | 0.91 | PARP1 (0.54) | PARP1ALDH1A1HSD17B10ATMSMN1; SMN2 | |
| SCHEMBL31172939 | 0.89 | PARP1 (0.49) | PARP1ALDH1A1HSD17B10ATMSMN1; SMN2 | |
| SCHEMBL29772102 | 0.84 | PARP1 (0.44) | PARP1ALDH1A1MEN1KMT2A | |
| SCHEMBL25268281 | 0.81 | PARP1 (0.41) | PARP1ALDH1A1HSD17B10SMN1; SMN2CTSK | |
| SCHEMBL25212939 | 0.81 | PARP1 (0.41) | PARP1ALDH1A1HSD17B10SMN1; SMN2CTSK | |
| SCHEMBL25416105 | 0.81 | PARP1 (0.41) | PARP1ALDH1A1HSD17B10SMN1; SMN2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| EP-3534899-B1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS INC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| WO-2018089261-A2 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | IL2, NFATC1, IL2RA | PARP1 2093/4885ALDH1A1 3523/4885HSD17B10 3219/4885 |
| US-11897874-B2 | Compounds and methods for modulating Interleukin-2-inducible T-cell kinase | IL2, NFATC1, IL2RA | PARP1 2093/4885ALDH1A1 3523/4885HSD17B10 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.